Continuing Education Information: Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
© 2017 Harborside Press®
ARTICLE
Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Release date: November 16, 2017
Expiration date: November 16, 2018
Expected time to complete activity: 0.75 hour
| Annenberg Center for Health Sciences at Eisenhower 39000 Bob Hope Drive, Dinah Shore Bldg. Rancho Mirage, CA 92270 Voice: 760-773-4500 Fax: 760-773-4513 E-mail: contactce@annenberg.net |
Journal of the Advanced Practitioner in Oncology 94 N. Woodhull Road Huntington, NY 11743 Voice: 631-692-0800 Fax: 631-692-0805 E-mail: ckiffer@hbside.com |
© 2017, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.
This article is supported, in part, by an educational grant from the following companies: Pfizer, Boehringer Ingelheim. We appreciate that these companies recognize our need for editorial independence in the development of this, and all content that appears in JADPRO.
Faculty
Christopher J. Campen, PharmD, BCOP, Greenville Health System Cancer Institute—Pharmacy, Greenville, South Carolina
Activity Rationale and Purpose
Over the past two decades, biologics have had a huge impact on the treatment of cancer in multiple tumor types, and in many cases these agents have improved outcomes and survival. In oncology, a growing number of biosimilars have been approved and are in clinical use in Europe, and it is anticipated that many oncology biosimilars will be approved by the US Food and Drug Administration within the next 18 to 24 months. In light of the potential windfall of biosimilars in the pipeline, the need for education must be a priority. Thus, there is a significant need to educate health-care providers about the nature of these products, their manufacturing process, and how they differ from the original parent compounds.
Intended Audience
The activity’s target audience will consist of nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
Learning Objectives
After completing this educational activity, participants should be able to:
- Demonstrate a clear understanding of the chemical nature of biosimilars, and their differences from biologics and generics.
- Identify biosimilars with recent or pending FDA approvals, and recommendations for their clinical use.
- Be aware of biosimilar nomenclature to avoid any confusion between prescribed drug and parent biologic or other biosimilars.
- Understand the importance of pharmacovigilance to identify potential long-term adverse effects.
- Be prepared to clearly explain and discuss the concept of biosimilars with patients and their family members.
Continuing Education
Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, Harborside Medical Education, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.75 contact hour may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 0.75 contact hour.
Pharmacists. The knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program #0797-9999-17-099-H01-P. This program is designated for up to 0.75 contact hour (0.075 CEU) of continuing pharmacy education credit.
Financial Disclosures
All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Disclosures
Faculty
Christopher J. Campen, PharmD, BCOP, has received consulting fees/honoraria from Astellas.
ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.
Planners
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Sarah McGullam has nothing to disclose.
Lynn Rubin has nothing to disclose.
Lisa Ryan has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.
Annie Yueh has nothing to disclose.
Content Reviewers
Kelley D. Mayden, MSN, FNP, AOCNP®, IAC, has received consulting fees/honoraria and has served on the speakers bureau for Puma Biotechnology, and has also served on the speakers bureaus for Apobiologix and Takeda.
Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.
Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
To access the learning assessment and evaluation form online,
visit http://surveys.edmeasures.com/s3/Biosimilars-Print-Post-Test
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.